Format

Send to

Choose Destination
Eur J Endocrinol. 2018 Nov 1. pii: EJE-18-0282.R2. doi: 10.1530/EJE-18-0282. [Epub ahead of print]

MANAGEMENT OF ENDOCRINE DISEASE: Treatment breaks in long-term management of osteoporosis.

Author information

1
B Langdahl, Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N, Denmark.

Abstract

Osteoporosis is a common chronic disease and therefore a long-term management plan based on disease severity, comorbidities, other pharmacological treatments, gender, age, and patient preferences is necessary. Consideration of treatment breaks may be included in the long-term management plan if the patient has been treated with a bisphosphonate, the disease is less severe, the response to treatment has been satisfactory, and the risk of future fracture is estimated to be low. This perspective reviews the current evidence for long-term treatment with bisphosphonates and off treatment effects. Approaches to decision making and monitoring of treatment breaks are discussed.

PMID:
30444721
DOI:
10.1530/EJE-18-0282

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center